Oncoinvent ASA operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Oncoinvent ASA's Operating Margin % or its related term are showing as below:
CHIX:ONCINo'
s Operating Margin % Range Over the Past 10 Years
Min: -78569.41 Med: -24479.8 Max: -593.35
Current: -866.56
CHIX:ONCINo's Operating Margin % is ranked worse than 77.44% of 944
companies
in the Biotechnology industry
Industry Median: -86.83
vs CHIX:ONCINo: -866.56
Oncoinvent ASA's 5-Year Average Operating Margin % Growth Rate was 55.10% per year.
Oncoinvent ASA's Operating Income for the
six
months ended in Dec. 2025 was kr-84.68 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was kr-139.26 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Oncoinvent ASA Operating Margin % Related Terms
Oncoinvent ASA Operating Margin % Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Oncoinvent ASA's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Operating Margin % of -746.23% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #731 out of 944 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Oncoinvent ASA's Operating Margin % too high?
Oncoinvent ASA's current Operating Margin % is -746.23%. Based on the distribution chart, Oncoinvent ASA ranks #731 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #731 out of 944 companies for Operating Margin %. This places Oncoinvent ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Operating Margin % is -746.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Operating Margin % of -746.23%. The stock's GF Value™ is kr20,399.27, compared to a current price of kr1,039.91 — trading 94.9% below its estimated fair value. The current Operating Margin % is -746.23%. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Operating Margin % is -746.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 94.9% below its estimated GF Value™ of kr20,399.27.
Key valuation signals for CHIX:ONCINO:
Operating Margin %: -746.23%
GF Value™: kr20,399.27 vs. price of kr1,039.91 (94.9% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
